Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma
HemaSphere · 2025-11 · 9 (11)
DOI: 10.1002/hem3.70248 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 27.11.2025. Verfasst von Efrat Luttwak und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Lymphoma Service Memorial Sloan Kettering Cancer Center New York New York United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on outcomes remains uncertain. We retrospectively evaluated 276 adults with large B‐cell lymphoma (LBCL) treated with CD19‐directed CAR‐T therapy (axi‐cel, tisa‐cel, or liso‐cel) between 2016 and 2023 at a single institution. Cumulative corticosteroid dose was defined as the total dose administered within 21 days of infusion. Corticosteroids were administered to 105 patients (38%), initiated at a median of 5 days post‐infusion (interquartile range [IQR] 3–7) for CRS (38%), ICANS (15%), or both (47%). Use was more frequent with axi‐cel (P < 0.001), although the cumulative dose and duration were similar across products. To assess the impact of corticosteroid exposure, we carried out a 21‐day landmark analysis. Corticosteroid exposure, modeled as a time‐dependent covariate, was not significantly associated with infection risk, non‐relapse mortality, or inferior overall survival (OS) or progression‐free survival (PFS). However, in a landmark analysis, patients receiving above‐median cumulative corticosteroid doses had a significantly higher risk of infection compared to those receiving below‐median corticosteroid doses or no corticosteroids (P = 0.042). In a landmark multivariable analysis, corticosteroid cumulative dose was associated with increased late hematologic toxicity (adjusted hazard ratio [HR] 1.02, 95% CI 1.02–1.03). Finally, in a sensitivity analysis excluding patients with Grade ≥4 CRS/ICANS, corticosteroid cumulative dose remained unassociated with OS or relapse, but was linked to shorter PFS (adjusted HR 1.04, 95% CI 1.01–1.06). These findings support the safe yet judicious use of corticosteroids to manage CAR‐T toxicities in LBCL.
Autor:innen und Institutionen
- Department of Medicine, Lymphoma Service Memorial Sloan Kettering Cancer Center New York New York United States.
- Department of Medicine Weill Cornell Medical College New York New York United States.
- Department of Biostatistics and Epidemiology Memorial Sloan Kettering Cancer Center New York New York United States.
- Department of Medicine Cellular Therapy Service, Memorial Sloan Kettering Cancer Center New York New York United States.
- Department of Medicine, Adult Bone Marrow Transplant Service Memorial Sloan Kettering Cancer Center New York New York United States.
- IRCCS San Raffaele Scientific Institute, Lymphoma Unit Milan Italy.
ORCID-Profile: Efrat Luttwak, Miguel-Angel Perales
Förderung
- NCI NIH HHS
Zitieren
APA
Luttwak, E., Nemirovsky, D., Devlin, S. M., Boardman, A. P., Cassanello, G., Corona, M., Luan, D., Dahi, P. B., Abia, A. L., Falchi, L., Landego, I., Lin, R. J., Lue, J. K., Palomba, L. M., Park, J. H., Raj, S. S., Rejeski, K., Rivas Delgado, A., Scordo, M., …, & Shouval, R. (2025). Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma. HemaSphere, 9(11). https://doi.org/10.1002/hem3.70248
Vancouver
Luttwak E, Nemirovsky D, Devlin SM, Boardman AP, Cassanello G, Corona M, et al. Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma. HemaSphere. 2025;9(11). doi:10.1002/hem3.70248
BibTeX
@article{Luttwak2025,
author = {Luttwak, Efrat and Nemirovsky, David and Devlin, Sean M and Boardman, Alexander P and Cassanello, Giulio and Corona, Magdalena and Luan, Danny and Dahi, Parastoo B and Abia, Alejandro Luna De and Falchi, Lorenzo and Landego, Ivan and Lin, Richard J and Lue, Jeniffer K and Palomba, Lia M and Park, Jae H and Raj, Sandeep S and Rejeski, Kai and Rivas Delgado, Alfredo and Scordo, Michael and Tomas, Ana Alarcon and Shah, Gunjan L and Perales, Miguel-Angel and Salles, Gilles and Shouval, Roni},
title = {Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {11},
doi = {10.1002/hem3.70248}
}
EUVIMED